Samsung Epis Holdings stock
0126Z0.KSKSCHealthcareISIN KR70126Z0002
41Score 41 out of 100, Weak
Price and trend
54 / 100
Price history
−22% since 2025The chart shows daily closing prices since 24 Nov 2025, adjusted for stock splits and excluding dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 24% below it.
Normal: the price is neither overheated nor sold off (RSI 54).
The price is 54% below its 52-week high. Largest decline since 24 Nov 2025: 59% (December 2025 to October 2026).
Chart figures for advanced users
- SMA 50$253.74
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$341.50
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)54
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$228.62
- The lowest closing price of the last twelve months.
- Resistance$556.93
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Samsung Epis Holdings belongs to the Biotechnology industry (South Korea) and, with a market value of $6.4B, is number 62 of 289 companies in its industry on MEQIRI.
- MEQIRI Score 41 out of 100 (Weak): rank 514 of 702 in Healthcare, median 53.
- The P/E is 18.2 (Biotechnology median 45.8, own median of recent years 36.1).
Show more
- Our model puts fair value at $650.68, with the price 60% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Modestly valuedP/E 18.2, Biotechnology median 45.8, own median 36.1.Valuation 75
Weaknesses
- Negative free cash flowFree cash flow −$455.72M over the last 12 months.Fundamentals 15
- Volatile share priceVolatility 79% a year over the last 12 months.Stability 46
Its standout strength is valuation, while profitability and fundamentals hold the score back.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk not measured
How well MEQIRI warnsFor stocks from Japan, China, Hong Kong, Taiwan, Korea, Canada, India and Brazil we only show crash risk once a separate backtest shows that it warns as well there as in the US and Europe.
Valuation
Valuation signal
Possible value trapIn our model the price counts as cheap below $433.78 and expensive above $1,301.35 (uncertainty very high, based on the price swings of the past year).
Possible value trap: looks cheap, but score below 50, weak balance sheet.
Valuation metrics
From earnings times the industry P/E (45.8) alone; there are no viable cash flows for the cash-flow model.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 6%, operating −23%, net 34%. Last 12 months: net 9%.
Debt & balance sheet
latest quarterDebt is low, but interest coverage is weak. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 1 Feb 2027in 80 days
- Last reported
- 23 Apr 2026EPS reported 2.65
Analyst estimates
Analysts have raised their 2027 earnings estimate by 30.2% since 26 Oct 2026.
- Earnings per share
- 14,577.36+28.1%
- Revenue
- $1.82T−2.9%
- Earnings per share
- 13,498.35+30.2%
- Revenue
- $1.94T−7.7%
MEQIRI has stored the estimates since 26 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
What happened at Samsung Epis Holdings
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 41
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- Belite BioBLTE $6.76B45
- Arrowhead PharmaceuticalsARWR $6.66B30
- ImmunityBioIBRX $6.46B37
- BioconBIOCON.NS $6.42B41
- Ligand PharmaceuticalsLGND $6.33B60
- CG OncologyCGON $6.27B41
- Hangzhou Tigermed Consulting300347.SZ $6.12B46
- Mirum PharmaceuticalsMIRM $6.09B38
ETFs that hold Samsung Epis Holdings
Held by 12 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| Franklin FTSE Korea UCITS ETFFLXK | 0.11% | 0.09% | €3.93B |
| Avantis Emerging Markets Equity UCITS ETF USD AccAVEM | 0.04% | 0.35% | €284.54M |
| Vanguard FTSE Developed Asia Pacific ex Japan UCITS ETF (USD) DistributingVGEJ | 0.03% | 0.15% | €2.61B |
Show 5 more
| Franklin FTSE Asia ex China ex Japan UCITS ETFFVSJ | 0.02% | 0.14% | €547.95M |
| iShares Dow Jones Global Leaders Screened UCITS ETF USD (Acc)IUSL | 0.01% | 0.60% | €2.04B |
| Vanguard FTSE Developed World UCITS ETF (USD) AccumulatingVGVF | 0.00% | 0.12% | €10.33B |
| Vanguard FTSE All-World UCITS ETF (USD) AccumulatingVWCE | 0.00% | 0.14% | €79.59B |
| Amundi Prime All Country World UCITS ETF AccWEBN | 0.00% | 0.07% | €8.95B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = ₩1,334.10)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 21 Oct 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.